Statin treatment in the elderly: How much do we know?

Archives of Medical Science

Volumn 9, Issue 4, 2013, Pages 585-588

  Rizzo, Manfredi ^a,b   Nikolic, Dragana ^a   Banach, Maciej ^c   Montalto, Giuseppe ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b Euro Mediterranean Institute of Science and Technology   (Italy)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; TRIACYLGLYCEROL;

AGED; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; LIPOPROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84883326730     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2013.37275     Document Type: Review

References (35)

1. Lakatta EG, Levy D. Arterial and cardiac aging: Major shareholders in cardiovascular disease enterprises. Part I: Aging arteries: A "set up" for vascular disease. Circulation 2003; 107: 139-46.
2. Kesteloot H, Sans S, Kromhout D. Dynamics of cardiovascular and all-cause mortality in Western and Eastern Europe between 1970 and 2000. Eur Heart J 2006; 27: 107-13.
3. Banach M, Aronow WS. Hypertension therapy in the older adults-do we know the answers to all the questions? The status after publication of the ACCF/AHA 2011 expert consensus document on hypertension in the elderly. J Hum Hypertens 2012; 26: 641-3.
4. Leis M, Gijsbers G. Report on Active and Healthy Ageing - A Long-term View up to 2050. Updated with results from the expert workshop on "Active and Healthy Ageing". 31.01.2011, Brussels. European Foresight Platform, 2011.
5. Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2011; 123: 2434-506.
6. Barylski M, Malyszko J, Rysz J, Mysliwiec M, Banach M. Lipids, blood pressure, kidney - what was new in 2011? Arch Med Sci 2011; 7: 1055-66.
7. Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375: 2215-22.
8. Barylski M, Nikfar S, Mikhailidis DP, et al. Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy: A meta-analysis of 11 randomized controlled trials involving 21,295 participants. Pharmacol Res 2013; 72: 35-44.
9. Weverling-Rijnsburger AW, Jonkers IJ, van Exel E, Gussekloo J, Westendorp RG. High-density vs low-density lipoprotein cholesterol as the risk factor for coronary artery disease and stroke in old age. Arch Intern Med 2003; 163: 1549-54.
10. Milionis HJ, Elisaf MS, Mikhailidis DP. Lipid abnormalities and cardiovascular risk in the elderly. Curr Med Res Opin 2008; 24: 653-7.
11. Otocka-Kmiecik A, Mikhailidis DP, Nicholls SJ, Davidson M, Rysz J, Banach M. Dysfunctional HDL: A novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res 2012; 51: 314-24.
12. Rizzo M, Berneis K. Low-density lipoprotein size and cardiovascular risk assessment. QJM 2006; 99: 1-14.
13. Campos H, Blijlevens E, McNamara JR, et al. LDL particle size distribution. Results from the Framingham Offspring Study. Arterioscler Thromb 1992; 12: 1410-9.
14. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): A prospective study. Lancet 2001; 358: 2026-33.
15. Austin MA, Mykkanen L, Kuusisto J, et al. Prospective study of small LDLs as a risk factor for non-insulin dependent diabetes mellitus in elderly men and women. Circulation 1995; 92: 1770-8.
16. Mikhailidis DP, Elisaf M, Rizzo M, et al. "European panel on low density lipoprotein (LDL) subclasses": A statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol 2011; 9: 533-71.
17. Szadkowska I, Stanczyk A, Aronow WS, et al. Statin therapy in the elderly: A review. Arch Gerontol Geriatr 2010; 50: 114-8.
18. Lai HM, Aronow WS, Mercando AD, et al. The impact of statin therapy on long-term cardiovascular outcomes in an outpatient cardiology practice. Arch Med Sci 2012; 8: 53-6.
19. Deedwania P, Stone PH, Bairey Merz CN, et al. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: Results of the Study Assessing Goals in the Elderly (SAGE). Circulation 2007; 115: 700-7.
20. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet 2003; 361: 2005-16.
21. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 2002; 360: 1623-30.
22. Berthold HK, Gouni-Berthold I. Lipid-lowering drug therapy in elderly patients. Curr Pharm Des 2011; 17: 877-93.
23. Kalantzi KJ, Milionis HJ, Mikhailidis DP, Goudevenos JA. Lipid lowering therapy in the elderly: Is there a benefit? Curr Pharm Des 2006; 12: 3945-60.
24. Sheppard JP, Singh S, Fletcher K, McManus RJ, Mant J. Impact of age and sex on primary preventive treatment for cardiovascular disease in the West Midlands, UK: Cross sectional study. BMJ 2012; 345: E4535.
25. Petersen LK, Christensen K, Kragstrup J. Lipid-lowering treatment to the end? A review of observational studies and RCTs on cholesterol and mortality in 80+-year olds. Age Ageing 2010; 39: 674-80.
26. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation 2002; 106: 1024-8.
27. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769-818.
28. Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: The treatment-risk paradox. JAMA 2004; 291: 1864-70.
29. Aronow WS. Pharmacologic therapy of lipid disorders in the elderly. Am J Geriatr Cardiol 2002; 11: 247-56.
30. Banach M, Mikhailidis DP, Kjeldsen SE, Rysz J. Time for new indications for statins? Med Sci Monit 2009; 15: MS1-5.
31. Howe C, Weiss B. Hyperlipidemia in older adults: To treat or not to treat? 2010; Available from: Http://www.reynolds. med.arizona.edu/EduProducts/ providerSheets/Hyperlipide mia.pdf
32. Athyros VG, Katsiki N, Tziomalos K, et al. Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: A post hoc analysis of the GREACE study. Arch Med Sci 2013; 9: 418-26.
33. Rizzo M, Berneis K, Spinas GA, Rini GB, Kapur NK. Quantitative and qualitative effects of rosuvastatin on LDL-cholesterol: What is the clinical significance? Int J Clin Pract 2009; 63: 478-85.
34. Shekhar Pandey A, Bissonnette S, Boukas S, Rampakakis E, Sampalis JS. Effectiveness and tolerability of ezetimibe co-administered with statins versus statin dose-doubling in high-risk patients with persistent hyperlipidemia: The EZE(STAT)2 trial. Arch Med Sci 2011; 7: 767-75.
35. Banach M, Hering D, Narkiewicz K, Myśliwiec M, Rysz J, Malyszko J. Lipids, blood pressure, kidney - what was new in 2012? Int J Pharmacol 2012; 8: 659-78.